Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

Mesa Laboratories, Inc. (NASDAQ:MLAB - Get Rating) Director Evan Guillemin sold 3,692 shares of the firm's stock in a transaction that occurred on Thursday, August 18th. The shares were sold at an average price of $196.12, for a total transaction of $724,075.04. Following the completion of the sale, the director now owns 28,776 shares in the company, valued at approximately $5,643,549.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB traded down $5.65 during mid-day trading on Friday, reaching $192.80. 248 shares of the company's stock were exchanged, compared to its average volume of 35,561. The business's fifty day moving average price is $199.50 and its 200-day moving average price is $227.07. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.90 and a quick ratio of 2.29. Mesa Laboratories, Inc. has a twelve month low of $178.32 and a twelve month high of $333.42.

Mesa Laboratories (NASDAQ:MLAB - Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The medical instruments supplier reported $0.52 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($1.05). Mesa Laboratories had a positive return on equity of 5.80% and a negative net margin of 0.78%. The business had revenue of $50.45 million for the quarter, compared to analyst estimates of $52.63 million. As a group, equities research analysts forecast that Mesa Laboratories, Inc. will post 6.08 earnings per share for the current fiscal year. Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 15th. Stockholders of record on Wednesday, August 31st will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.33%. The ex-dividend date is Tuesday, August 30th. Mesa Laboratories's payout ratio is presently -213.33%. Institutional Investors Weigh In On Mesa Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in MLAB. Oregon Public Employees Retirement Fund increased its position in shares of Mesa Laboratories by 4.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,057 shares of the medical instruments supplier's stock worth $675,000 after acquiring an additional 88 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Mesa Laboratories by 77.1% during the fourth quarter. New York State Common Retirement Fund now owns 6,286 shares of the medical instruments supplier's stock worth $2,062,000 after purchasing an additional 2,737 shares during the last quarter. Advisor Group Holdings Inc. boosted its holdings in Mesa Laboratories by 14.9% during the fourth quarter. Advisor Group Holdings Inc. now owns 1,285 shares of the medical instruments supplier's stock worth $422,000 after purchasing an additional 167 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in Mesa Laboratories by 18.3% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 4,885 shares of the medical instruments supplier's stock worth $1,603,000 after purchasing an additional 755 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its holdings in Mesa Laboratories by 7.6% during the fourth quarter. Envestnet Asset Management Inc. now owns 9,749 shares of the medical instruments supplier's stock worth $3,199,000 after purchasing an additional 686 shares during the last quarter. 91.90% of the stock is owned by institutional investors. Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of Mesa Laboratories from a "hold" rating to a "sell" rating in a research report on Friday, August 5th.Mesa Laboratories Company Profile (Get Rating)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries.Featured ArticlesGet a free copy of the StockNews.com research report on Mesa Laboratories (MLAB)Apple’s Stock Could Be On The Verge Of Another 30% RallyNear-Term Headwinds Present An Opportunity In Ross StoresIf You Hate Speed Cameras, Then You’ll Like Verra Mobility Stock Institutional Support For TJX Companies May Cap GainsIs Sanofi A Buy, Despite Recent Stumbles?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Mesa Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesa Laboratories wasn't on the list.

While Mesa Laboratories currently has a "N/A" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

David McNatt discusses ESG investing and offers ways to avoid pitfalls and to understand exactly what kinds of companies you are buying.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.